Change - Announcement of Cessation::Resignation of Chief Executive Officer

Issuer & Securities

Issuer/ Manager
PHARMESIS INTERNATIONAL LTD.
Securities
PHARMESIS INTERNATIONAL LTD. - SG1BH6000003 - BFK
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
01-Jul-2016 17:12:07
Status
New
Announcement Sub Title
Resignation of Chief Executive Officer
Announcement Reference
SG160701OTHRF29P
Submitted By (Co./ Ind. Name)
Mr Jiang Yun
Designation
Executive Director
Description (Please provide a detailed description of the event in the box below)
Resignation of Chief Executive Officer

Additional Details

Name Of Person
Wu Xuedan
Age
54
Is effective date of cessation known?
Yes
If yes, please provide the date
01/07/2016
Detailed Reason (s) for cessation
Mr Wu Xuedan ("Mr Wu") has relinquished his position as Chief Executive Officer and remains as Executive Director of the Company with effect from 1 July 2016 due to the reshuffling of the Board members and realignment of duties.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
05/01/2009
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
2
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
4
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer
Role and responsibilities
As Chief Executive Officer, Mr Wu oversees the overall Management and operations of the Group as well as supervises the research and development activities.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Shareholding interest in the listed issuer and its subsidiaries?
No
Past (for the last 5 years)
Nil
Present
1. Chengdu Kinna Pharmaceutical Ltd
2. Sichuan Longlife Pharmaceutical Co. Ltd
3. Chengdu Pharmesis Pharmaceutical Co. Ltd
4. Top Entrepreneur Limited